Abstract:45 Background: New animal models of esophageal cancer are required to accelerate research into novel treatment strategies. Mouse xenografts used in pre-clinical drug testing are typically derived from cell lines, but several esophageal cancer cell lines have been contaminated (PMID 20075370). Xenografts implanted from surgically resected human tumors are a potentially viable model, and may better recapitulate the characteristics of the original tumor. We describe the feasibility of such an approach. Methods: 2-10 mm esophageal carcinoma fragments obtained from resected patient tumors were implanted directly into NOD/SCID mice. Tumors that grew beyond 1.5 cm in diameter were passaged serially. Pathologic properties were assessed from passage to passage. Potential clinicopathological predictors of engraftment were evaluated. Results: Of the 63 patients with tumors used for implantation, 67% were male; median age 66 (range 31-89); 31% node negative disease; 69% node positive disease; 12% metastatic; 55% received neoadjuvant therapy; 12% had prior Barrett's esophagus; 46% had pre-existing heartburn; 88% were distal esophageal/GE junction cancers. Engraftment occurred in 14/43 (33%) adeno-, 1/14 (7%) squamous, and 1/1 adenosquamous carcinomas (p=0.05; 5 others were rare tumors e.g. granular or small cell). Engraftment occurred in 6/31 well/moderately vs 7/18 poorly differentiated tumors (p=0.08). Because we amended our implantation procedures, we compared engraftment rates pre- (7/39; 18%) and post-amendment (8/23; 35%; p=0.13). The primary architecture of the xenografted tissue remained similar pathologically for up to 5+ passages. None of the following variables predicted for engraftment (p>0.20 each comparison): cancer location, age, gender, history of heartburn, pre-operative therapy, presence of Barrett's esophagus, disease stage, or recurrence of primary cancer. Conclusions: Creation of esophageal cancer xenografts from primary human resected specimens is feasible. Adenocarcinomas, higher tumor grade, and newer implantation strategies were associated with improved engraftment. We are treating these models with chemotherapy to discover new pharmacogenomic predictive biomarkers. No significant financial relationships to disclose.

Research Progress of Esophageal Cancer Mouse Models

Genetically engineered mouse models of esophageal cancer

Study on establishment of esophageal carcinoma animal models

Patient-derived Xenograft Models in Hepatopancreatobiliary Cancer

Progress in models of pancreatic cancer

Progress of experimental animal model of gastric carcinoma

Mouse Models for Head and Neck Squamous Cell Carcinoma

Experimental mouse models for translational human cancer research

Mouse Tumor-Bearing Models as Preclinical Study Platforms for Oral Squamous Cell Carcinoma

Research progress in the establishment of pancreatic cancer models and preclinical applications

Patient-derived tumor models: a suitable tool for preclinical studies on esophageal cancer

Research progress in animal models of cholangiocarcinoma

Establishment of human esophageal cancer xenograft model in immunocompetent mice and explorations of related immunological changes

Patient-derived Human Tumour Tissue Xenografts in Immunodeficient Mice: a Systematic Review

Advances in Prostate Cancer Research Models: from Transgenic Mice to Tumor Xenografting Models

Establishment of Primary Human Esophageal Xenografts: Rationale for Selection and Cancer Model

Establishment and Characterization of Esophageal Squamous Cell Carcinoma Patient-Derived Xenograft Mouse Models for Preclinical Drug Discovery

Application of Animal Models in Cancer Research: Recent Progress and Future Prospects

Transgenic and gene knockout mice in gastric cancer research

Esophageal adenocarcinoma models: a closer look

Research Status of Mouse Models for Non-Small-Cell Lung Cancer (NSCLC) and Antitumor Therapy of Traditional Chinese Medicine (TCM) in Mouse Models